NEW YORK (GenomeWeb News) – Harvard Bioscience's board of directors on Friday unanimously rejected a buyout offer from Skystone Advisors for $5 a share. 
 
Skystone, a Cayman Islands-incorporated LLC with operations in Boston, has been investing in Harvard Bio since 2005 and currently owns around 15 percent of the company. Its offer represents a premium of around 11 percent over Harvard Bio’s trading price of $4.50 Friday afternoon, and values the firm at roughly $154 million based on 30.8 million shares outstanding.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.